Transform Wealth LLC Has $3.25 Million Stock Position in Novartis AG (NYSE:NVS)

Transform Wealth LLC lifted its holdings in Novartis AG (NYSE:NVS - Free Report) by 22.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,292 shares of the company's stock after purchasing an additional 5,141 shares during the quarter. Transform Wealth LLC's holdings in Novartis were worth $3,254,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Dimensional Fund Advisors LP grew its stake in shares of Novartis by 23.1% in the second quarter. Dimensional Fund Advisors LP now owns 7,407,692 shares of the company's stock worth $788,626,000 after purchasing an additional 1,389,610 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Novartis by 0.6% during the first quarter. Janus Henderson Group PLC now owns 2,568,728 shares of the company's stock valued at $248,473,000 after buying an additional 16,015 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Novartis by 0.6% during the first quarter. Principal Financial Group Inc. now owns 2,523,334 shares of the company's stock valued at $244,082,000 after buying an additional 14,686 shares in the last quarter. Mondrian Investment Partners LTD boosted its stake in Novartis by 40.1% during the first quarter. Mondrian Investment Partners LTD now owns 2,065,739 shares of the company's stock valued at $199,819,000 after buying an additional 590,830 shares in the last quarter. Finally, Magnetar Financial LLC boosted its stake in Novartis by 53.7% during the first quarter. Magnetar Financial LLC now owns 1,906,046 shares of the company's stock valued at $184,372,000 after buying an additional 666,104 shares in the last quarter. Institutional investors own 13.12% of the company's stock.

Novartis Stock Up 0.3 %

Novartis stock traded up $0.34 during mid-day trading on Wednesday, hitting $116.56. The company's stock had a trading volume of 620,242 shares, compared to its average volume of 1,349,910. The firm's 50 day moving average is $115.98 and its 200 day moving average is $107.63. The company has a market cap of $238.25 billion, a PE ratio of 14.73, a price-to-earnings-growth ratio of 1.71 and a beta of 0.57. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72. Novartis AG has a 52-week low of $92.19 and a 52-week high of $120.92.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Thursday, July 18th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.10. Novartis had a return on equity of 34.56% and a net margin of 33.76%. The firm had revenue of $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the business earned $1.83 EPS. On average, analysts anticipate that Novartis AG will post 7.52 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on NVS. Barclays raised Novartis to a "strong sell" rating in a research note on Monday, June 24th. Bank of America downgraded Novartis from a "buy" rating to a "neutral" rating and reduced their target price for the company from $135.00 to $130.00 in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Novartis in a report on Friday, July 19th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $121.00 target price (up from $119.00) on shares of Novartis in a report on Thursday, September 5th. Finally, Jefferies Financial Group downgraded Novartis from a "buy" rating to a "hold" rating in a report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novartis currently has an average rating of "Hold" and a consensus target price of $120.70.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.